Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir
- 1 July 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (7) , 3517-3521
Abstract
Dolutegravir (DTG) is an unboosted, once-daily integrase inhibitor currently in phase 3 trials. Two studies evaluated the effects of etravirine (ETR) alone and in combination with ritonavir (RTV)-boosted protease inhibitors (PIs) on DTG pharmacokinetics (PK) in healthy subjects. DTG 50 mg every 24 h (q24h) was administered alone for 5 days in period 1, followed by combination with ETR at 200 mg q12h for 14 days in period 2 (study 1) or with ETR/lopinavir (LPV)/RTV at 200/400/100 mg q12h or ETR/darunavir (DRV)/RTV at 200/600/100 mg q12h for 14 days in period 2 (study 2). PK samples were collected on day 5 in period 1 and day 14 in period 2. All of the treatments were well tolerated. ETR significantly decreased exposures of DTG, with geometric mean ratios of 0.294 (90% confidence intervals, 0.257 to 0.337) for the area under the curve from time zero until the end of the dosage interval (AUC 0-τ ), 0.484 (0.433 to 0.542) for the observed maximum plasma concentration ( C max ), and 0.121 (0.093 to 0.157) for the plasma concentration at the end of the dosage interval ( C τ ). ETR combined with an RTV-boosted PI affected the exposure of DTG to a lesser degree: ETR/LPV/RTV treatment had no effect on the DTG plasma AUC 0-τ and C max , whereas the C τ increased by 28%. ETR/DRV/RTV modestly decreased the plasma DTG AUC 0-τ , C max , and C τ by 25, 12, and 37%, respectively. Such effects of ETR/LPV/RTV and ETR/DRV/RTV are not considered clinically relevant. The combination of DTG and ETR alone should be avoided; however, DTG may be coadministered with ETR without a dosage adjustment if LPV/RTV or DRV/RTV is concurrently administered.Keywords
This publication has 10 references indexed in Scilit:
- The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2011
- Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirineAntiviral Therapy, 2010
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Integrase Inhibitors: A Novel Class of Antiretroviral AgentsAnnals of Pharmacotherapy, 2010
- Etravirine–raltegravir, a marked interaction in HIV-1-infected patients: about four casesAIDS, 2009
- Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2008
- Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative IndividualsAntimicrobial Agents and Chemotherapy, 2005
- Efavirenz-Induced Decrease in Plasma Amprenavir Levels in Human Immunodeficiency Virus-Infected Patients and Correction by RitonavirAntimicrobial Agents and Chemotherapy, 2000